Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VIP and tolerance induction in autoimmunity.

F Rosignoli1, M Torroba, Y Juarranz

  • 1Dept. Biología Celular, Facultad de Biologia, UCM 28040 Madrid, Spain.

Annals of the New York Academy of Sciences
|August 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Is severity related to the utilization of resources? An exploration of the Duke Severity of Illness Scale (DUSOI)].

Atencion primaria·1998
Same author

Transfusion-related acute lung injury associated with an NA1-specific antigranulocyte antibody.

Haematologica·1998
Same author

The two poles of the lymphocyte: specialized cell compartments for migration and recruitment.

Cell adhesion and communication·1998
Same author

Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.

British journal of cancer·1998
Same author

Delayed-type hypersensitivity to subcutaneous enoxaparin.

Allergy·1998
Same author

Occupational asthma by Anisakis simplex.

The Journal of allergy and clinical immunology·1998

Vasoactive intestinal peptide (VIP) prevents type 1 diabetes in nonobese diabetic mice by reducing inflammation and promoting regulatory T cells. VIP treatment restores immune tolerance to pancreatic islets, offering a potential therapeutic strategy.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetes Research

Background:

  • Vasoactive intestinal peptide (VIP) exhibits potent anti-inflammatory and immunoregulatory properties.
  • VIP influences immune responses by promoting a Th2 cytokine profile.

Purpose of the Study:

  • To investigate the therapeutic potential of VIP in preventing type 1 diabetes.
  • To elucidate the immunomodulatory mechanisms underlying VIP's protective effects in a mouse model.

Main Methods:

  • Treatment of nonobese diabetic (NOD) mice with VIP starting at 4 weeks of age.
  • Assessment of diabetes incidence, insulitis severity, and cytokine profiles.
  • Analysis of regulatory T cell markers (FoxP3, TGF-beta) and Th1 transcription factor (T-bet) in pancreatic tissues.

Related Experiment Videos

Main Results:

  • VIP treatment completely prevented diabetes development in NOD mice.
  • VIP-treated mice exhibited significantly milder insulitis compared to controls.
  • VIP administration reduced circulating Th1 cytokine levels.
  • Pancreatic tissues showed increased expression of regulatory T cell markers (FoxP3, TGF-beta) and decreased T-bet.

Conclusions:

  • VIP effectively prevents type 1 diabetes in a preclinical model.
  • VIP restores immune tolerance to pancreatic islets by promoting local regulatory T cell differentiation and function.
  • VIP represents a promising therapeutic candidate for type 1 diabetes treatment.